Cancer Letters
Volume 294, Issue 2 , Pages 220-228 , 28 August 2010

Enhanced anti-tumor activity by the combination of a conditionally replicating adenovirus mediated interleukin-24 and dacarbazine against melanoma cells via induction of apoptosis

  • Guan Jiang

      Affiliations

    • Department of Dermatology, Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China
    • Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou 221002, China
    • Present address: Clinic of Skin and Venereal Diseases, Center for Disease Control and Prevention of Xuzhou City, Xuzhou 221006, China.
    • These authors contributed equally to this paper.
    • ,
  • Yan-Qun Liu

      Affiliations

    • Department of Dermatology, Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China
    • These authors contributed equally to this paper.
    • Corresponding Author InformationCorresponding authors. Address: Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou 221002, China (J.-N. Zheng).
    • ,
  • Zhi-Ping Wei

      Affiliations

    • Department of Dermatology, Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China
    • ,
  • Dong-Sheng Pei

      Affiliations

    • Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou 221002, China
    • ,
  • Li-Jun Mao

      Affiliations

    • Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou 221002, China
    • Laboratory of Urology, Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China
    • ,
  • Jun-Nian Zheng

      Affiliations

    • Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou 221002, China
    • Laboratory of Urology, Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China
    • Corresponding Author InformationCorresponding authors. Address: Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou 221002, China (J.-N. Zheng).

Received 8 September 2009 ,Revised 2 December 2009 ,Accepted 4 February 2010.

References 

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin. 2007;57:43–66
  2. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene. 2003;22:3138–3151
  3. Eberle J, Kurbanov BM, Hossini AM, Trefzer U, Fecker LF. Overcoming apoptosis deficiency of melanoma–hope for new therapeutic approaches. Drug Resist. Update. 2007;10:218–234
  4. Mhaidat NM, Zhang XD, Allen J, Avery-Kiejda KA, Scott RJ, Hersey P. Temozolomide induces senescence but not apoptosis in human melanoma cells. Br. J. Cancer. 2007;97:1225–1233
  5. La Porta CA. Drug resistance in melanoma: new perspectives. Curr. Med. Chem. 2007;14:387–391
  6. Quirin C, Mainka A, Hesse A, Nettelbeck DM. Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells. Int. J. Cancer. 2007;121:2801–2807
  7. Loo TL, Housholder GE, Gerulath AH, Saunders PH, Farquhar D. Mechanism of action and pharmacology studies with DTIC (NSC-45388). Cancer Treat. Rep. 1976;60:149–152
  8. Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, Engebraaten O. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. J. Gene Med. 2007;9:440–451
  9. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30years?. Eur. J. Cancer. 2004;40:1825–1836
  10. Miller AJ, Mihm MC. Melanoma. New Engl. J. Med. 2006;355:51–65
  11. Xie T, Nguyen T, Hupe M, Wei ML. Multidrug resistance decreases with mutations of melanosomal regulatory genes. Cancer Res. 2009;69:992–999
  12. Jiang H, Su ZZ, Lin JJ, Goldstein NI, Young CS, Fisher PB. The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc. Natl. Acad. Sci. USA. 1996;93:9160–9165
  13. Eager R, Harle L, Nemunaitis J. Ad-MDA-7; INGN 241: a review of preclinical and clinical experience. Expert Opin. Biol. Ther. 2008;8:1633–1643
  14. Cunningham CC, Chada S, Merritt JA, Tong A, Senzer N, Zhang Y, et al. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol. Ther. 2005;11:149–159
  15. Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin. Cancer Res. 2004;10:5299–5312
  16. Yoon AR, Kim JH, Lee YS, Kim H, Yoo JY, Sohn JH, et al. Markedly enhanced cytolysis by E1B-19-kD-deleted oncolytic adenovirus in combination with cisplatin. Hum. Gene Ther. 2006;17:379–390
  17. Liu XY, Gu JF. Targeting gene-virotherapy of cancer. Cell Res. 2006;16:740
  18. Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He L, et al. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum. Gene Ther. 2005;16:845–858
  19. Zheng JN, Pei DS, Sun FH, Liu XY, Mao LJ, Zhang BF, et al. Potent antitumor efficacy of interleukin-18 delivered by conditionally replicative adenovirus vector in renal cell carcinoma-bearing nude mice via inhibition of angiogenesis. Cancer Biol. Ther. 2009;8:599–606
  20. Zheng JN, Pei DS, Sun FH, Zhang BF, Liu XY, Gu JF, et al. Inhibition of renal cancer cell growth by oncolytic adenovirus armed short hairpin RNA targeting hTERT gene. Cancer Biol. Ther. 2009;8:84–91
  21. He XP, Su CQ, Wang XH, Pan X, Tu ZX, Gong YF, et al. E1B-55-kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer. Cancer Lett. 2009;285:89–98
  22. Pan Q, Liu B, Liu J, Cai R, Wang Y, Qian C. Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL. Mol. Cell Biochem. 2007;304:315–323
  23. Zhang Y, Qin X, Zhao L, Wang Y, Liu X, Yao L. Combination of ZD55-MnSOD therapy with 5-FU enhances antitumor efficacy in colorectal cancer. J. Cancer Res. Clin. Oncol. 2008;134:219–226
  24. Qian W, Liu J, Tong Y, Yan S, Yang C, Yang M, et al. Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis. Leukemia. 2008;22:361–369
  25. Upreti M, Chu R, Galitovskaya E, Smart SK, Chambers TC. Key role for Bak activation and Bak–Bax interaction in the apoptotic response to vinblastine. Mol. Cancer Ther. 2008;7:2224–2232
  26. Gupta P, Su ZZ, Lebedeva IV, Sarkar D, Sauane M, Emdad L, et al. mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol. Ther. 2006;111:596–628
  27. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change?. Cancer. 2007;109:455–464
  28. Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broemeling L, Yekell S, Chada S, et al. Loss of MDA-7 expression with progression of melanoma. J. Clin. Oncol. 2002;20:1069–1074
  29. Emdad L, Lebedeva IV, Su ZZ, Gupta P, Sauane M, Dash R, et al. Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biol. Ther. 2009;8:391–400
  30. Fisher PB, Sarkar D, Lebedeva IV, Emdad L, Gupta P, Sauane M, et al. Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicol. Appl. Pharmacol. 2007;224:300–307
  31. Chen L, Chen D, Gong M, Na M, Li L, Wu H, et al. Concomitant use of Ad5/35 chimeric oncolytic adenovirus with TRAIL gene and taxol produces synergistic cytotoxicity in gastric cancer cells. Cancer Lett. 2009;284:141–148
  32. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 2000;6:879–885
  33. Kaliberova LN, Krendelchtchikova V, Harmon DK, Stockard CR, Petersen AS, Markert JM, et al. CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma. Cancer Gene Ther. 2009;16:794–805
  34. Liu XY. Targeting gene-virotherapy of cancer and its prosperity. Cell Res. 2006;16:879–886
  35. Eberle J, Fecker LF, Hossini AM, Kurbanov BM, Fechner H. Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma. Exp. Dermatol. 2008;17:1–11
  36. Lesinski GB, Raig ET, Guenterberg K, Brown L, Go MR, Shah NN, et al. IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis. Cancer Res. 2008;68:8351–8360

PII: S0304-3835(10)00080-7

doi: 10.1016/j.canlet.2010.02.003

Cancer Letters
Volume 294, Issue 2 , Pages 220-228 , 28 August 2010

Article Tools

* Image Usage & Resolution